Success Metrics

Clinical Success Rate
86.5%

Based on 45 completed trials

Completion Rate
87%(45/52)
Active Trials
10(14%)
Results Posted
33%(15 trials)
Terminated
7(10%)

Phase Distribution

Ph phase_2
39
55%
Ph not_applicable
1
1%
Ph phase_1
11
15%
Ph phase_3
14
20%

Phase Distribution

11

Early Stage

39

Mid Stage

14

Late Stage

Phase Distribution65 total trials
Phase 1Safety & dosage
11(16.9%)
Phase 2Efficacy & side effects
39(60.0%)
Phase 3Large-scale testing
14(21.5%)
N/ANon-phased studies
1(1.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

81.8%

45 of 55 finished

Non-Completion Rate

18.2%

10 ended early

Currently Active

10

trials recruiting

Total Trials

71

all time

Status Distribution
Active(11)
Completed(45)
Terminated(10)
Other(5)

Detailed Status

Completed45
Recruiting8
Terminated7
unknown5
Withdrawn3
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
71
Active
10
Success Rate
86.5%
Most Advanced
Phase 3

Trials by Phase

Phase 111 (16.9%)
Phase 239 (60.0%)
Phase 314 (21.5%)
N/A1 (1.5%)

Trials by Status

withdrawn34%
not_yet_recruiting11%
recruiting811%
active_not_recruiting23%
unknown57%
completed4563%
terminated710%

Recent Activity

10 active trials
Showing 5 of 71
active_not_recruitingphase_2

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

NCT05432791
recruitingphase_2

Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

NCT04305548
recruitingphase_2

Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

NCT04383119
completedphase_2

Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma

NCT01303094
recruitingphase_2

Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS

NCT07076186
View all 71 trials

Clinical Trials (71)

Showing 20 of 71 trialsScroll for more
NCT05432791Phase 2

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Active Not Recruiting
NCT04305548Phase 2

Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

Recruiting
NCT04383119Phase 2

Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Recruiting
NCT01303094Phase 2

Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma

Completed
NCT07076186Phase 2

Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS

Recruiting
NCT04008238Not Applicable

Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients

Completed
NCT07444619Phase 1

A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas

Not Yet Recruiting
NCT04794127Phase 2

Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.

Completed
NCT04076579Phase 2

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Completed
NCT06263231Phase 3

A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

Active Not Recruiting
NCT02234050Phase 2

Trabectedin for Recurrent Grade II/III Meningioma

Completed
NCT05597917Phase 3

tTF-NGR Randomized Study - STS

Recruiting
NCT06524583Phase 2

Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Recruiting
NCT04535271Phase 2

Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

Recruiting
NCT03138161Phase 1

SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma

Recruiting
NCT04979442Phase 3

Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma

Terminated
NCT03023124Phase 2

Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor

Completed
NCT03127215Phase 2

Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors

Completed
NCT03884972Phase 1

Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor

Withdrawn
NCT02367924

Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma

Completed

Drug Details

Intervention Type
DRUG
Total Trials
71